Analysts at a trio of investment advisory firms downgraded their estimates for C.R. Bard (NYSE:BCR) stock, which hasn’t fared well recently.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Med-tech companies may not get as much bang for their buck in emerging markets, according to a dim forecast for the BRIC economies by investment bank Goldman Sachs.
Indices created by the bank predicted flat 7.9 percent growth for Brazil, Russia, India and China through 2012.
MASSDEVICE ON CALL — North Carolina researchers built the first functional anal sphincters in a laboratory, and the organs developed blood flow and maintained function when implanted in mice.
While mouse studies are a far cry from preparation for human use, the lab-made sphincters could one day lead to treatment for urinary and fecal incontinence.
Edwards Lifesciences Corp. (NYSE:EW) finally a little love from The Street when Goldman Sachs upgraded the med-tech giant to "conviction buy," which means Sachs expects the stock to outperform.
That’s good news for Irvine, Calif.-based Edwards, whose stock has consistently slumped on bad news for the past month. Equities analysts Rodman & Renshaw just downgraded the company from "market perform" to "underperform" late last month.
John Paulson, the billionaire whose hedge fund is the largest shareholder of Boston Scinetific Corp. (NYSE:BSX) stock, is seeking shelter from the fallout billowing around his head after he was named but not charged in a Securities & Exchange Commission indictment of Goldman Sachs Co. over sub-prime mortgages.
The SEC filed a civil suit against Goldman Sachs April 16, accusing the firm of misleading the public with statements concerning the sub-prime mortgage securities whose collapse helped precipitate the near-meltdown of the global financial market.